Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

News SummaryMost relevantAll newsSector newsTweets 

St. Jude Medical, Inc. : St Jude To Stop Selling Another Version Of Defibrillator Wires

share with twitter share with LinkedIn share with facebook
share via e-mail
04/04/2012 | 03:48pm CET

St. Jude Medical Inc. (STJ) will stop selling another version of its defibrillator wires in an effort to head off potential problems like those the medical-device maker is currently battling with its Riata and Riata ST wires.

The Riata defibrillator wires, called leads, are no longer on the market but are still implanted in thousands of patients in the U.S. In a medical journal last month, prominent cardiologist Robert G. Hauser wrote that the cables are responsible for at least 20 deaths.

Wednesday, the company said it will cease selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart. Roughly 171,000 QuickSite and QuickFlex leads have been sold worldwide.

The decision comes as St. Jude has confirmed 39 cases of the metal wires wearing through their silicone covering, leading to an incidence rate of 2.3 in every 10,000 leads. Still, it stressed that its decision to stop selling the wires is a proactive one.

"It is important to note, however, that the overall safety and reliability of QuickSite and QuickFlex leads continues to be comparable to currently available CRT leads from other manufacturers," the company wrote.

The wire leads connect life-saving medical devices, which are placed under the skin in the shoulder area, to the heart and delivers a jolt that restores proper rhythm. Because of the constant pounding motion of the heart, the thin leads can be damaged.

Shares closed Tuesday at $43.80 and were inactive in premarket trading. The stock is up roughly 36% from lows hit late last year when the Food and Drug Administration termed the Riata defibrillator issues as a Class I recall, which applies to grave dangers like chance of death.

   -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ST. JUDE MEDICAL, INC.
01/12 ST JUDE MEDICAL : Patent Issued for Catheter with a Mechanism for Omni-Direction..
01/12 ST JUDE MEDICAL : Trademark Application for "ENDURANCE" Filed by St. Jude Medica..
01/12 ST JUDE MEDICAL : Patent Issued for Delivery System Deflection Mechanism (USPTO ..
01/12 ST JUDE MEDICAL : Flawed implant shows that medical devices are vulnerable to ha..
01/11 CORRECTION : Correction for Wednesday, Jan. 11, 2017
01/10 ST JUDE MEDICAL : FDA says St. Jude heart devices vulnerable to hacking
01/09 ST JUDE MEDICAL : Contract award - 65-- va263-17-p-1504 pros v23 618 272784 card..
01/07 ST JUDE MEDICAL : Federal Contracts Awarded to Companies in Minnesota (Jan. 7)
01/07 ST JUDE MEDICAL : $26,450 Federal Contract Awarded to St. Jude Medical
01/07 ST JUDE MEDICAL : $25,235 Federal Contract Awarded to St. Jude Medical
More news
Sector news : Medical Devices & Implants
08:49aDJLUXOTTICA FOUNDER : A Lifetime of Deals -- WSJ
08:49aDJLUXOTTICA : Merger to Create Eyewear Giant -- WSJ
08:48aDJWHAT'S NEWS : Business & Finance -- WSJ
01/16 ESSILOR INTL : Luxottica's merger helps Del Vecchio manage family risks
01/16DJLUXOTTICA : Another Big Splash by Italy's Eyewear King
More sector news : Medical Devices & Implants
News from SeekingAlpha
01/11 Medtech Mergers And Acquisitions Regresses To The Mean In 2016
01/09 ABBOTT CLOSES ST. JUDE MEDICAL DEAL : Good For Shareholders?
01/04 Political Ructions, Poor Deal-Making And Scandal - A Bad Year For Big-Cap Med..
01/04 Time To Rush For The Exit?
01/03 IDEXX Labs to join S&P 500, Chemours bumps up to S&P MidCap 400
Financials ($)
More Financials
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
Consensus details
EPS Revisions
More Estimates Revisions
Michael T. Rousseau President, Chief Executive Officer & Director
Daniel J. Starks Executive Chairman
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SMITH & NEPHEW PLC1.31%13 192
GLAUKOS CORP15.10%1 325
More Results